via University of Southampton
Scientists from the Antibody and Vaccine group at the University of Southampton have discovered a way to transform antibody drugs previously developed to treat autoimmunity into antibodies with powerful anti-cancer activity through a simple molecular “switch”.
This work, published in the journal Cancer Cell, focuses on a molecule called CD40 which is present on the surface of immune cells and controls both autoimmunity and cancer. In autoimmunity, CD40 is thought to be over-stimulated, increasing the chance of the immune system attacking healthy tissues; whereas in cancer, CD40 is believed to be under-stimulated, enabling tumour cells to evade the immune system. Targeting of CD40 with antibody drugs is ongoing in therapeutic interventions for both diseases.
Accordingly, antibody drugs have been developed to either activate (agonists) or suppress (antagonists) the CD40 immune pathway. Researchers at the Centre for Cancer Immunology in Southampton, led by Professors Mark Cragg and Martin Glennie now reveal that an antagonist CD40 antibody can be transformed into an agonist by simply modifying the “constant” domain of the antibody. The antagonist-turned agonist “trick” was shown for three different antagonists, being driven by the hinge part of the constant domain that controls the flexibility of the antibody. One of these antibodies, was shown to be a “super”-agonist that could stimulate the immune system and cure cancer more effectively in preclinical models than the best CD40-targeting antibody currently in clinical trial.
“Being able to toggle between an autoimmune drug and a cancer medicine with a simple switch is really exciting.” said Dr Xiaojie Yu, first author of the study. “We gained a deeper understanding of the mechanism through which CD40 becomes activated, and eagerly look forward to applying this technology to more drug candidates.”
“Our findings build on a history of CD40 research here in Southampton and were surprising and exciting in equal measure,” said Professor Mark Cragg, senior author of the study. “Taking an antibody that suppresses the immune system and turning it on its head, to activate the immune system for cancer through a relatively simple process is unprecedented. More than that, the same approach could be used for other immune targets and we look forward to seeing testing this in the near future”.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Cleveland Clinic receives two grants totaling $4.6m to study cancer drug in Alzheimer'son January 27, 2021 at 11:44 am
The National Institute of Aging (NIA), part of the National Institutes of Health (NIH), and the Alzheimer's Drug Discovery Foundation (ADDF) awarded five-year grants of $3.2 million and $1.4 million, ...
- Anti-cancer drug discovery made easier with gold nanostructureson January 27, 2021 at 2:22 am
Scientists design a novel 3D cell culture-based electrical platform for high-throughput anti-cancer drug testing using a new type of gold nanostructure.
- Dr. Martin J. Murphy Named Emeritus Director of CEO Roundtable on Cancer Board of Directorson January 27, 2021 at 1:39 am
After more than two decades of dedication to advance the prevention, diagnosis, and treatment of cancer, Dr. Martin J. Murphy has retired from the Board of Directors of the CEO Roundtable on Cancer.
- MU's research reactor to provide radioisotope for new cancer treatmenton January 26, 2021 at 2:42 pm
The MU Research Reactor Center will provide material to a pharmaceutical company to manufacture a new cancer therapy.
- Tilray® Selected by French National Agency to Supply GMP-Certified Medical Cannabis Products in Franceon January 26, 2021 at 8:00 am
Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been selected by ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Rep. Bentz appointed to House Natural Resources Committeeon January 27, 2021 at 8:11 am
Oregon U.S. Rep Cliff Bentz now is serving on the House Natural Resources Committee. Bentz in a press release said he was honored to receive the appointment to a committee well-suited to Oregon’s vast ...
- Correction: Generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potentialon January 27, 2021 at 8:04 am
CD40/CD86 refer to mononuclear cells stained with a rat IgG2a isotype control antibody. The conclusions of the article were not affected. The authors apologize for any inconvenience caused. Department ...
- Pediatric immune thrombocytopenia: apoptotic markers may help in predicting the disease course | Pediatric Researchon January 27, 2021 at 6:31 am
In all, 15–30% of pediatric immune thrombocytopenia (ITP) patients will remain chronically thrombocytopenic at 1 year post diagnosis. All attempts to classify patients at diagnosis have proven ...
- Alamos Gold Extends High-Grade Gold Mineralization Laterally and Down-Plunge at Island Goldon January 27, 2021 at 4:06 am
Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today reported new results from surface and underground exploration drilling at the Island Gold Mine, further extending high-grade gold ...
- Death threats and intimidation of public officials signal Trump's autocratic legacyon January 26, 2021 at 3:16 pm
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Shelley Inglis, University of Dayton (THE CONVERSATION) As the impeachment trial ...